Evidence Snapshot

CDK2/Cyclin A2

CHEMBL3038469 PROTEIN COMPLEX Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:15Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 6:25 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL3038469

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats CDK2/Cyclin A2 as ChEMBL target CHEMBL3038469, mapped to UniProt P24941. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

CDK2/Cyclin A2

PROTEIN COMPLEX · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL3038469

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P24941

Cyclin-dependent kinase 2

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why CDK2/Cyclin A2 matters

As of 2026-09-13

CDK2/Cyclin A2 is reviewed as Cyclin-dependent kinase 2 (UniProt P24941); the current evidence base includes 4 approved drugs, 2208 compounds, and 366 assays, with lead potency reaching pChEMBL 9.8.

Protein context

Cyclin-dependent kinase 2

Cyclin-dependent kinase 2 Sequence length is 298 aa.

Review this target as CDK2/Cyclin A2, mapped to UniProt P24941. ChEMBL maps the protein component as Cyclin-dependent kinase 2. Sequence length is 298 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P24941 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 2208 compounds, and 366 assays for this target. The dominant activity type is IC50. CHEMBL5808524 is the current potency anchor at pChEMBL 9.8.

Use CHEMBL5808524 as the tractability anchor when discussing potency (pChEMBL 9.8).

Activity source · ChEMBL 36 via Core Engine

4 approved pChEMBL 9.8

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why CDK2/Cyclin A2 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P24941, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2208

Total Compounds

366

Total Assays

Approved Drugs

IC50: 1611.0, KI: 185.0, KD: 53.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5808524	9.8	IC50	—
No preferred name CHEMBL261720	9.7	IC50	—
No preferred name CHEMBL388978	9.4	IC50	—
No preferred name CHEMBL5837976	9.4	IC50	—
No preferred name CHEMBL5739950	9.2	IC50	—